Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 5, 2002

View Archived Issues

Drug pipeline for anxiety

Thalidomide plus temozolomide in malignant gliomas

Good tolerability profile reported for tetracycline COL-3 in high-grade glioma

EMD-121794 reported to be well tolerated in patients with malignant gliomas

Enzyme-inducing anticonvulsants improve tolerability of CCI-779 in patients with CNS tumors

Improved tolerability of PZA in glioblastoma multiforme patients receiving anticonvulsants

Tolerability of intratumoral DTI-015 in recurrent malignant glioma

T-138067 inactive in astrocytoma and glioblastoma multiforme

Promising data reported for dendritic cell vaccine in GBM

Boston Scientific acquires Smart Therapeutics

Bayer describes inhibitors of PDE7B for asthma and bone disorders

Novel nicotinic acetylcholine and/or 5-HT receptor ligands covered by Merck patent

Two series of cytokine production inhibitors with utility in arthritis and heart failure

New CRF antagonists under study at GSK

BMS designs new series of PDE7 inhibitors

Sankyo scientists prepare benzopyran compounds with multiple mechanisms of action

Senju claims novel compounds with potential in reflux esophagitis

Encouraging results from phase II trial with IP-751 in neuropathic pain

Solvay acquires exclusive worldwide rights to cetrorelix

Preclinical efficacy of Cerebragel in brain cancer

Organon and Entelos expand research collaboration

FDA approves Pegasys and Copegus combination therapy in hepatitis C

Swissmedic approves Glivec for first-line treatment of CML

Celltech returns rights to CF program to Targeted Genetics

Allos to begin rolling NDA submission for RSR-13

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...